Who was studied?
One patient with PD-L1-positive recurrent, advanced Hürthle cell carcinoma.
What does the publication report?
The authors described an antitumor response after progression following surgery, radiotherapy and targeted treatment.
Safety findings
The abstract does not provide a complete graded adverse-event account.
How should we interpret it?
A single patient cannot establish efficacy or predict an individual outcome. Prior and concurrent treatments limit attribution.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review · DOI: 10.3389/fonc.2021.782646 · PMID: 34888252
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.